Using MRI to understand brain tumor biology in patients with glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial utilizes magnetic resonance imaging (MRI) to investigate the biology of brain tumors in patients diagnosed with resectable glioblastoma. The study aims to identify imaging biomarkers that correlate with tumor characteristics and patient outcomes, particularly focusing on the expression of specific proteins and genetic material in tumors with varying diffusion measurements. Patients will undergo one MRI scan prior to surgical resection to gather data that may help predict which individuals will benefit from bevacizumab therapy. The findings could lead to more personalized treatment approaches for glioblastoma patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients \> 18 years of age
* Patients with newly diagnosed, suspected or recurrent glioblastoma (GBM) patients with enhancing tumors greater than 1.5 mL clinically indicated for surgical resection. Recurrent GBM must have occurred more than 3 months after the end of radiation therapy per Response Assessment in Neuro-Oncology Criteria (RANO) guidelines

Exclusion Criteria:

* Counterindication to magnetic resonance imaging (MRI) (Patient has a pacemaker or metal in the body)
* Patients \< 18 years of age

Where it's running

• UCLA / Jonsson Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Benjamin M Ellingson — UCLA / Jonsson Comprehensive Cancer Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Sitagliptin plus bevacizumab for recurrent grade 4 glioma

  This study tests whether adding sitagliptin to bevacizumab can help people whose recurrent glioblastoma or other grade 4 gliomas respond to treatment and to find a safe dose when used with bevacizumab.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07541781

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• ERAS-801 for operable or recurrent EGFR-altered IDH-wildtype Grade IV glioblastoma or astrocytoma

  This trial tests ERAS-801, a brain-penetrant EGFR blocker, to see if it is safe and changes tumor metabolism in adults with resectable or recurrent IDH-wildtype Grade IV glioblastoma or astrocytoma that have EGFR amplification or mutation.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California and 1 other locations · NCT07089641

• Metabolic profiling of glioblastoma using advanced imaging techniques

  This study is testing new imaging techniques to see how glioblastoma tumors use energy and nutrients, which could help doctors understand the tumors better and improve treatment options.

  Recruiting at 2 sites Early Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania and 1 other locations · NCT06613841

• Testing Troriluzole for recurrent glioblastoma treatment

  This study is testing if Troriluzole can help people with recurrent glioblastoma feel better when given before and after surgery compared to just after surgery.

  Recruiting at 3 sites Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06552260

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.